Nathan Connell: What Is The “Mild Equivalent” For Hemophilia A That Is Achieved While on Emicizumab?
Nathan Connell, MD, MPH, FACP, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared an insightful post on LinkedIn:
”A common question that comes up in hemophilia clinic is: What is the “mild equivalent” for hemophilia A that is achieved while on emicizumab? We know that secondary hemostasis isn’t completely normalized for people taking emicizumab, but patients often ask what their (equivalent) factor VIII level would be if it could be measured. At its most basic, disorders of secondary hemostasis are rooted in an inability to generate thrombin, so thrombin generation assays (TGAs) are theoretically an attractive method to offer a window into the answer for this question; however, differences in TGAs and lack of standardization make it difficult to settle on a single number.
This Haemophilia Journal publication by Daniel Kraemmer and colleagues (including Cihan Ay) highlights the heterogeneity in estimates depending on which TGA parameters are utilized in the analysis, and suggests a conservative estimate is anywhere from 15% – 37%, supporting clinical experience with the therapy but highlighting the need for better methods to assess hemostasis in vivo.”
Read the full article here.
Article: Estimating the Factor VIII-Equivalent Activity of Emicizumab Using Global Assays of Haemostasis
Authors: Daniel Kraemmer , Cihan Ay, Judit Rejtő, Georg Heinze, Peter Quehenberger, Ingrid Pabinger, Oliver Königsbrügge
Stay updated on the latest scientific advancements in the field of hemophilia with Hemostasis Today.
-
Aug 4, 2025, 06:00Genotype–Phenotype Understanding in Hemophilia B: Commentary on Factor IX Missense Variants
-
Aug 4, 2025, 05:47National Health Center Week – Recognizing the Vital Role of HTCs in Specialized Care
-
Aug 4, 2025, 05:33Women with Hemophilia Finally Heard: “DISMISSED” Premieres August 22
-
Aug 4, 2025, 04:58Women with Inherited Bleeding Disorders: Overcoming Diagnostic and Clinical Challenge
-
Aug 4, 2025, 01:37EAHAD Launches Italian Booklet to Support Young Girls With Bleeding Disorders During Their First Period
-
Aug 4, 2025, 01:59Michael Makris Posts Haemophilia Journal Article Reassessing UK Blood Inquiry
-
Aug 4, 2025, 01:09Manuel Monreal Congratulates Authors Ahead of JTH Publication: VTE-Predict Score Validated in RIETE Cohort
-
Aug 3, 2025, 17:48Nathan Connell: What Is The "Mild Equivalent" For Hemophilia A That Is Achieved While on Emicizumab?
-
Aug 3, 2025, 03:54Cedric Hermans on the Inspiring Impact of the WFH Humanitarian Aid Program Worldwide
-
Aug 2, 2025, 20:14Sebastian Szmit Shares Patients’ Perspectives on Decision‑Making for Antithrombotic Therapy in Advanced Cancer
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Aug 4, 2025, 05:20NBCA: Alexis’s DVT Diagnosis Came Without Warning - Learn How She Caught It Early
-
Aug 4, 2025, 00:50NBCA: After Losing Her Daughter to a Blood Clot, Charita Fights to Save Others
-
Aug 3, 2025, 18:10Andrew Agwunobi Congrats Dr. Oladipo Cole and The Whole Team at the Connecticut Bleeding Disorder Center
-
Aug 3, 2025, 12:03Elias Bouchi Presents Werfen EEMEA Talks on Hemostasis: Clot Stories Season 3
-
Jul 31, 2025, 15:37Sano Genetics: “Unreasonable” Leadership with Benny Sorenson of Hemab